Vancomycin administration: The impact of multidisciplinary interventions

Journal of Clinical Pathology

Volumn 60, Issue 10, 2007, Pages 1155-1159

  Crowley, Rachel K ^a   Fitzpatrick, F ^a   Solanki, D ^a   FitzGerald, S ^a   Humphreys, H ^a   Smyth, E G ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG MONITORING; HOSPITAL MANAGEMENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL EDUCATION; PATIENT ASSESSMENT; PATIENT CARE; PATIENT MONITORING; PHARMACIST; PRIORITY JOURNAL;

EID: 35348990279     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.044727     Document Type: Article

References (17)

1. Palmer-Toy DE. Therapeutic monitoring of vancomycin. Arch Pathol Lab Med 2000;124:322-3.
2. Finch RG, Eliopoulos GM. Safety and efficacy of glycopeptide antibiotics. J Antimicrob Chemother 2005;55(Suppl 2):ii5-13.
3. Eng RH, Wynn L, Smith SM, et al. Effect of intravenous vancomycin on renal function. Chemotherapy 1989;35:320-5.
4. Wilson AP. Comparative safety of teicoplanin and vancomycin. Int J Antimicrob Agents 1998;10:143-52.
5. Hammett-Stabler CA, Johns T. Laboratory guidelines for monitoring of antimicrobial drugs. National Academy of Clinical Biochemistry. Clin Chem 1998;44:1129-40.
6. Catchpole C, Hastings JG. Measuring pre- and post-dose vancomycin levels - time for a change? J Med Microbiol 1995;42:309-11.
7. Saunders NJ. Why monitor peak vancomycin concentrations? Lancet 1994;344:1748-50.
8. Tan WH, Brown N, Kelsall AW, et al. Dose regimen for vancomycin not needing serum peak levels? Arch Dis Child Fetal Neonatal Ed 2002;87:F214-16.
9. Pou L, Rosell M, Lopez R, et al. Changes in vancomycin pharmacokinetics during treatment. Ther Drug Monit 1996;18:149-53.
10. Crist KD, Nahata MC, Ety J. Positive impact of a therapeutic drug-monitoring program on total aminoglycoside dose and cost of hospitalization. Ther Drug Monit 1987;9:306-10.
11. Tobin CM, Darville JM, Thomson AH, et al. Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire. J Antimicrob Chemother 2002;50:713-18.
12. Wysocki M, Thomas F, Wolff M. Why monitor peak vancomycin concentrations? Lancet 1995;345:646.
13. Andres I, Lopez R, Pou L, et al. Vancomycin monitoring: one or two serum levels? Ther Drug Monit 1997;19:614-19.
14. Bates DW, Soldin SJ, Rainey PM, et al. Strategies for physician education in therapeutic drug monitoring. Clin Chem 1998;44:401-7.
15. Ansari F, Gray K, Nathwani D, et al. Outcomes of an intervention to improve hospital antibiotic prescribing: interrupted time series with segmented regression analysis. J Antimicrob Chemother 2003;52:842-8.
16. Ritchie S, Scanlon N, Lewis M, et al. Use of a preprinted sticker to improve the prescribing of prophylactic antibiotics for hip fracture surgery. Qual Saf Health Care 2004;13:384-7.
17. Jamtvedt G, Young JM, Kristoffersen DT, et al. Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2003;(3):CD000259.